Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Wuhan Ammunition Life-tech Files Hong Kong IPO Prospectus, Pioneering Methylation-Based Early Cancer Detection with Liver and Urothelial Cancer Tests

Fineline Cube Apr 8, 2026
Company Deals

Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline

Fineline Cube Apr 8, 2026
Company Deals

Biogen Licenses Alloy Therapeutics’ AntiClastic ASO Platform to Advance Next-Generation Antisense Therapy Research

Fineline Cube Apr 8, 2026
Company Deals

Everest Medicines to Acquire EverSea Medicines Singapore for $250M, Expanding Asia-Pacific Chronic Disease Portfolio

Fineline Cube Apr 8, 2026
Company Deals

Takeda Terminates Neuroscience Partnership with Denali, Returns Frontotemporal Dementia Candidate DNL593 for Strategic Realignment

Fineline Cube Apr 8, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

UniXell Biotechnology Secures NMPA IND Approval for UX-GIP001, World’s First iPSC-Derived Cell Therapy for Drug-Resistant Epilepsy

Fineline Cube Apr 9, 2026
Company Drug

Shionogi Secures $119M BARDA Contract for Fetroja Antibiotic as Biothreat Countermeasure

Fineline Cube Apr 9, 2026
Company Deals Medical Device

Shenzhen Concemed Medtech Secures Hundreds of Millions in Series A+ Funding for Endoscopy Expansion

Fineline Cube Jul 8, 2025

Shenzhen Concemed Medical Technology Co., Ltd., a China-based endoscope specialist, has reportedly secured “hundreds of...

Company Drug

RemeGen Submits New Indication Application for Disitamab Vedotin in Urothelial Carcinoma

Fineline Cube Jul 8, 2025

RemeGen Ltd (HKG: 9995) announced that the National Medical Products Administration (NMPA) in China has...

Company Drug

Grand Pharma’s SIR-Spheres Y-90 Gets FDA Accelerated Approval for Unresectable HCC

Fineline Cube Jul 8, 2025

China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced that SIR-Spheres Y-90 resin microspheres (SIR-Spheres), a...

Company Drug

Boehringer Ingelheim Starts Phase III THULITE Study for BI 1815368 in Diabetic Macular Edema

Fineline Cube Jul 8, 2025

German pharmaceutical major Boehringer Ingelheim announced the initiation of the Phase III THULITE study to...

Company Deals

GSK Completes Acquisition of Boston Pharma’s BP Asset IX for Efimosfermin Alpha

Fineline Cube Jul 8, 2025

UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced the completion of its acquisition of BP Asset IX, a...

Company Deals

Qilu Pharmaceutical Partners with Sagent Pharmaceuticals to Expand US Market Presence

Fineline Cube Jul 8, 2025

China-based Qilu Pharmaceutical Co., Ltd. this week announced a strategic partnership with US-headquartered Sagent Pharmaceuticals....

Policy / Regulatory

NMPA Releases 93rd Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Jul 8, 2025

The National Medical Products Administration (NMPA) has released the 93rd batch of reference drugs for...

Company Deals Drug

Roche’s Chugai Pharmaceutical Partners with Gero to Develop Therapies for Age-Related Diseases

Fineline Cube Jul 8, 2025

Roche’s Japan-based subsidiary Chugai Pharmaceutical Co., Ltd. (TYO: 4519) announced this week a joint research...

Company Deals

CStone Pharmaceuticals Licenses Cejemly to Istituto Gentili for 23 Countries in Europe and the UK

Fineline Cube Jul 8, 2025

China-based CStone Pharmaceuticals (HKG: 2616) announced a licensing agreement with Istituto Gentili S.R.L., granting the...

Company Drug

Jiangsu CTTQ’s TQB2102 Receives Breakthrough Therapy Designation for HER2+ Breast Cancer

Fineline Cube Jul 8, 2025

Subsidiary of China based Sino Biopharmaceutical Ltd (HKG: 1177) Jiangsu Chia Tai Tianqing Pharmaceutical Co.,...

Company Drug

Wepon Medical Receives NMPA Clinical Approval for WP107 in Generalized Myasthenia Gravis

Fineline Cube Jul 8, 2025

Wepon Medical Holding Group Co., Ltd. (SHE: 002082) announced that it has received clinical approval...

Policy / Regulatory

China’s CDE Announces 95th Batch of Reference Preparations for Public Comment

Fineline Cube Jul 7, 2025

China’s Center for Drug Evaluation (CDE) has released the 95th batch of reference preparations for...

Policy / Regulatory

China Ministry of Finance Restricts EU-Imported Medical Devices in Government Procurement Over RMB45 Million

Fineline Cube Jul 7, 2025

China’s Ministry of Finance (MoF) has issued the “Notice on Implementing Relevant Measures for EU-Imported...

Company Drug

SCG Cell Therapy Obtains NMPA Approval for SCG101V in Chronic HBV Study

Fineline Cube Jul 7, 2025

China’s Center for Drug Evaluation of the National Medical Products Administration (NMPA) has approved SCG...

Company Medical Device

BGI Genomics Launches Mini Breast Cancer 76-Gene Detection System for Personalized Treatment

Fineline Cube Jul 7, 2025

China-based BGI Genomics Co., Ltd (SHE: 300676) announced the launch of its mini breast cancer...

Company Drug

AstraZeneca’s Imfinzi Approved in EU for Perioperative Treatment of Muscle-Invasive Bladder Cancer

Fineline Cube Jul 7, 2025

UK-based AstraZeneca (AZ, NASDAQ: AZN) announced that it has received marketing approval in the European...

Company Deals

Modella AI Collaborates with AstraZeneca to Accelerate Oncology Drug Development with AI

Fineline Cube Jul 7, 2025

US-based Modella AI, a leader in biomedical artificial intelligence (AI), announced a multi-year collaboration with...

Company Drug

CStone Pharmaceuticals Announces Phase III Trial Progress for Nofazinlimab in Hepatocellular Carcinoma

Fineline Cube Jul 7, 2025

China-based CStone Pharmaceuticals (HKG: 2616) announced the latest progress in its global multicenter Phase III...

Company Deals

Micot Raises Over RMB 100 Million in Series D Funding Led by Zheshang Venture Capital

Fineline Cube Jul 7, 2025

Micot, a polypeptide new molecular entity (NME) drug developer with operations in mainland China, Hong...

Policy / Regulatory

NMPA Unveils Measures to Support High-End Medical Device Innovation with Full Lifecycle Regulation

Fineline Cube Jul 7, 2025

China’s National Medical Products Administration (NMPA) last week released the “Measures to Optimize Full-lifecycle Regulation...

Posts pagination

1 … 112 113 114 … 647

Recent updates

  • UniXell Biotechnology Secures NMPA IND Approval for UX-GIP001, World’s First iPSC-Derived Cell Therapy for Drug-Resistant Epilepsy
  • Shionogi Secures $119M BARDA Contract for Fetroja Antibiotic as Biothreat Countermeasure
  • Ascletis Pharma Advances Oral GLP-1R/Amylin Receptor Dual Agonist Combination ASC30/ASC39 for Obesity, Targeting Q3 FDA IND Submission
  • Basecare Medical Secures NMPA Category III Approval for Gems Series IVF Culture Media, Expanding China’s Domestic Embryo Culture Solutions
  • Wuhan Ammunition Life-tech Files Hong Kong IPO Prospectus, Pioneering Methylation-Based Early Cancer Detection with Liver and Urothelial Cancer Tests
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

UniXell Biotechnology Secures NMPA IND Approval for UX-GIP001, World’s First iPSC-Derived Cell Therapy for Drug-Resistant Epilepsy

Company Drug

Shionogi Secures $119M BARDA Contract for Fetroja Antibiotic as Biothreat Countermeasure

Others

Ascletis Pharma Advances Oral GLP-1R/Amylin Receptor Dual Agonist Combination ASC30/ASC39 for Obesity, Targeting Q3 FDA IND Submission

Others

Basecare Medical Secures NMPA Category III Approval for Gems Series IVF Culture Media, Expanding China’s Domestic Embryo Culture Solutions

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.